Replies to post #3993 on Biotech Values

[Skeptic]

From Harris Nesbitt...

"The company remains on target to release data on
its Phase III trial for wet AMD at the American Academy of Ophthalmology
meeting on October 23-26. Wet AMD affects 200,000 Americans annually and has a
prevalence rate of 1.5 million. Consequently, depending on the data, the
company has the potential to participate in a multi-billion-dollar market
opportunity. We expect the company to file an NDA in 4Q04 and receive FDA
approval in late 1H05."

I'm not sure how big of an event this will be given that ACL already has annual revenue of 3.7 billion. It might be good for a 20% move one way or another.